CDEK by Data4ThePeople

Sign in Sign up

← All drugs Report issue

maxipost

Small moleculeexperimental

Clinical trial activity

2 trials · 1 clinical orgs · 0 marketing orgs

Phase 1

0

Phase 2

0

Phase 3

0

Phase 4

0

Earliest trial started Apr 1, 2019 (NCT03887325)

Timeline

No events for the selected filters.

Mechanism of action

Voltage-gated potassium channel KCNQ3/KCNQ4ACTIVATOR
Voltage-gated potassium channel KCNQ3/KCNQ4 activator
Indication: Stroke
- Potassium voltage-gated channel subfamily KQT member 3 (KCNQ3) ↗
- Potassium voltage-gated channel subfamily KQT member 4 (KCNQ4) ↗
- Voltage-gated potassium channel subunit Kv7.4
- Voltage-gated potassium channel subunit Kv7.3
Voltage-gated potassium channel, KQT; KCNQ2(Kv7.2)/KCNQ3(Kv7.3)ACTIVATOR
Voltage-gated potassium channel, KQT; KCNQ2(Kv7.2)/KCNQ3(Kv7.3) activator
Indication: Stroke
- Potassium voltage-gated channel subfamily KQT member 2 (KCNQ2) ↗
- Potassium voltage-gated channel subfamily KQT member 3 (KCNQ3) ↗
- Voltage-gated potassium channel subunit Kv7.2
- Voltage-gated potassium channel subunit Kv7.3
Voltage-gated potassium channel subunit Kv7.2ACTIVATOR
KCNQ2 activator
Indication: Stroke
- Potassium voltage-gated channel subfamily KQT member 2 (KCNQ2) ↗
Calcium-activated potassium channel subunit alpha-1OPENER
KCNMA1 opener
Indication: Stroke
- Calcium-activated potassium channel subunit alpha-1 (KCNMA1) ↗
Voltage-gated potassium channel subunit Kv7.5ACTIVATOR
KCNQ5 activator
Indication: Stroke
- Potassium voltage-gated channel subfamily KQT member 5 (KCNQ5) ↗
Voltage-gated potassium channel subunit Kv7.4ACTIVATOR
KCNQ4 activator
Indication: Stroke
- Potassium voltage-gated channel subfamily KQT member 4 (KCNQ4) ↗

Chemistry & pharmacology

Loading structure…

SMILES

COc1ccc(Cl)cc1[C@]1(F)C(=O)Nc2cc(C(F)(F)F)ccc21

Mol. weight: 359.71 g/mol
Lipinski Ro5: Pass
Rule of 3: No
Chirality: Single Stereoisomer
Inorganic: No
Polymer: No

Oral

No

Parenteral

No

Topical

No

Sources

ChEMBLCHEMBL266510 ↗

Also known as

(5-chloro-2-methoxyphenyl)-1,3-dihydro-3-fluoro-6-(trifluoromethyl)-2h-indol-2-one
bms204352
bms 204352
bms-204352
bms-204352
bms-204352
flindokalner
flindokalner
maxipost
maxipost
maxipost

Clinical trials

NCT ID	Phase	Start date	Sponsor(s)
NCT05378074	N/A	Sep 1, 2022	University of Copenhagen
NCT03887325	N/A	Apr 1, 2019	University of Copenhagen

Showing 2 of 2 trials

Page 1 / 1

Organizations

Research & Development (1)

Organization	Org type	Trials	As lead sponsor	Phases	Earliest year
University of Copenhagen	Academic/Hospital	2	2	1	2019

1 organizations

Page 1 / 1